Bota Bio, a global industrial biotechnology company advancing sustainable biomanufacturing, today announced that it has raised more than $100 million in an oversubscribed Series B funding round. The financing was led by Sequoia Capital China. Other investors included previous backers Matrix Partners China, Source Code Capital, Sherpa Healthcare Partners, and 5Y Capital, among others. This Series B financing brings Bota Bio's total funding to $145 million to date.

Bota Bio is a global industrial biotechnology company focused on programming biological systems for the clean and efficient biomanufacturing of common household and industrial products. Bota Bio is led by an experienced, multidisciplinary team of industry veterans combining data and automation to translate biotechnologies into business value and consumer welfare.